Sackler family members pay $225M civil to resolve OxyContin marketing claims
Concurrent with the Purdue Pharma criminal resolution, individual Sackler family members paid $225M to resolve civil False Claims Act allegations that they directed and approved deceptive marketing of OxyContin while serving on Purdue's board. No individual Sackler faced criminal charges despite internal communications showing personal involvement in marketing strategy. Subsequent bankruptcy plan (2024 SCOTUS overturned the third-party-release shield) substantially expanded the family's later financial liability, but the 2020 resolution itself contained no admission of liability and no bar on continuing pharmaceutical-industry activities.